Harry M. Jansen Kraemer Jr.
Harry M. Jansen Kraemer Jr.'s purchase track record
How the stock did after each of Harry M. Jansen Kraemer Jr.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/4/2026 | OPCH | $784K | +12.1% | pending | — |
| 11/3/2025 | OPCH | $987K | +31.0% | -20.0% | +5.1% |
| 8/20/2025 | OPCH | $977K | +2.0% | +30.4% | +7.6% |
| 11/8/2024 | OPCH | $969K | +37.8% | +41.6% | -5.6% |
| 2/26/2024 | OPCH | $1.10M | -4.9% | +0.3% | +10.8% |
| 8/11/2023 | OPCH | $1.90M | -17.5% | -5.4% | +12.6% |
| 8/16/2021 | OPCH | $1.07M | +24.6% | +10.6% | -1.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
McKesson moves to acquire Option Care Health in $5.8B deal. Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Transaction History
| LDOS | ▲ Buy | Grant | 297 | $0 | 10/7/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 463 | $0 | 9/30/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 310 | $0 | 7/6/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 565 | $0 | 6/30/2026 | View on chart |
| OPCH | ▲ Buy | Grant | 8,997 | $0 | 5/20/2026 | View on chart |
| OPCH | ▲ Buy | Grant | 12,079 | $269K | 5/20/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 1,067 | $0 | 5/8/2026 | View on chart |
| OPCH | ▲ Buy | Open Market | 36,610 | $784K | 5/4/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 10 | $0 | 5/1/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 221 | $0 | 4/10/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 364 | $0 | 3/31/2026 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 3,345 | $251K | 2/20/2026 | View on chart |
| LDOS | ▼ Sell | Tax Withholding | 1,424 | $251K | 2/20/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 172 | $0 | 1/7/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 305 | $0 | 12/31/2025 | View on chart |
| OPCH | ▲ Buy | Open Market | 38,000 | $987K | 11/3/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 165 | $0 | 10/7/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 279 | $0 | 9/30/2025 | View on chart |
| OPCH | ▲ Buy | Open Market | 36,000 | $977K | 8/20/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 201 | $0 | 7/8/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 332 | $0 | 6/30/2025 | View on chart |
| OPCH | ▲ Buy | Grant | 5,034 | $0 | 5/14/2025 | View on chart |
| OPCH | ▲ Buy | Grant | 8,022 | $255K | 5/14/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 873 | $0 | 5/9/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 254 | $0 | 4/7/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 376 | $0 | 3/28/2025 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 4,070 | $257K | 2/21/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 214 | $0 | 1/10/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 355 | $0 | 12/31/2024 | View on chart |
| OPCH | ▲ Buy | Open Market | 43,000 | $969K | 11/8/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 304 | $0 | 9/27/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 326 | $0 | 6/28/2024 | View on chart |
| OPCH | ▲ Buy | Grant | 13,806 | $0 | 5/15/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 912 | $0 | 5/3/2024 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 4,788 | $252K | 5/2/2024 | View on chart |
| LDOS | ▼ Sell | Tax Withholding | 1,775 | $252K | 5/2/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 18 | $0 | 4/26/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 362 | $0 | 3/28/2024 | View on chart |
| OPCH | ▲ Buy | Open Market | 35,000 | $1.1M | 2/26/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 46 | $0 | 1/12/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 436 | $0 | 12/29/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 74 | $0 | 10/13/2023 | View on chart |
| LDOS | ▲ Buy | Grant | 482 | $0 | 9/29/2023 | View on chart |
| OPCH | ▲ Buy | Open Market | 55,000 | $1.9M | 8/11/2023 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 5,193 | $206K | 8/4/2023 | View on chart |
| LDOS | ▼ Sell | Tax Withholding | 2,095 | $206K | 8/4/2023 | View on chart |
| LDOS | ▼ Sell | Open Market | 3,098 | $300K | 8/4/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 75 | $0 | 7/14/2023 | View on chart |
| LDOS | ▲ Buy | Grant | 504 | $0 | 6/30/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 5,419 | $0 | 5/25/2023 | View on chart |
| OPCH | ▲ Buy | Grant | 12,630 | $0 | 5/17/2023 | View on chart |
| LDOS | ▲ Buy | Grant | 1,574 | $0 | 5/5/2023 | View on chart |
| LDOS | ▲ Buy | Grant | 17 | $0 | 4/28/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 57 | $0 | 4/14/2023 | View on chart |
| LDOS | ▲ Buy | Grant | 477 | $0 | 3/31/2023 | View on chart |
| OPCH | ▲ Buy | Grant | 6,933 | $0 | 3/15/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 62 | $0 | 1/13/2023 | View on chart |
| LDOS | ▲ Buy | Grant | 415 | $0 | 12/30/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 6,382 | $0 | 11/15/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 42 | $0 | 10/14/2022 | View on chart |
| LDOS | ▲ Buy | Grant | 492 | $0 | 9/30/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 32 | $0 | 7/8/2022 | View on chart |
| LDOS | ▲ Buy | Grant | 435 | $0 | 6/30/2022 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 10,523 | $333K | 5/26/2022 | View on chart |
| LDOS | ▼ Sell | Tax Withholding | 3,249 | $333K | 5/26/2022 | View on chart |
| LDOS | ▼ Sell | Open Market | 7,274 | $751K | 5/26/2022 | View on chart |
| OPCH | ▲ Buy | Grant | 9,555 | $0 | 5/20/2022 | View on chart |
| LDOS | ▲ Buy | Grant | 1,106 | $0 | 5/6/2022 | View on chart |
| LDOS | ▲ Buy | Grant | 14 | $0 | 4/29/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 36 | $0 | 4/8/2022 | View on chart |
| LDOS | ▲ Buy | Grant | 394 | $0 | 3/31/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 6 | $0 | 1/14/2022 | View on chart |
| LDOS | ▲ Buy | Grant | 481 | $0 | 12/30/2021 | View on chart |
| XRAY | ▲ Buy | Grant | 26 | $2K | 10/8/2021 | View on chart |
| LDOS | ▲ Buy | Grant | 432 | $0 | 9/30/2021 | View on chart |
| OPCH | ▲ Buy | Open Market | 44,742 | $960K | 8/17/2021 | View on chart |
| OPCH | ▲ Buy | Open Market | 5,258 | $113K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Leidos wins new defense and health contracts
Leidos Holdings recently secured new contracts for logistics support in the UK and health research for the U.S. Navy. These wins highlight the company's ongoing role in defense and health services. The stock is currently trading well below the average analyst target price, suggesting potential value for some investors.
Leidos wins new defense and health contracts. Leidos Holdings recently secured new contracts for logistics support in the UK and health research for the U.S. Navy. These wins highlight the company's ongoing role in defense and health services. The stock is currently trading well below the average analyst target price, suggesting potential value for some investors.